Trial Profile
A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with Inhibitors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2022
Price :
$35
*
At a glance
- Drugs Concizumab (Primary) ; Eptacog alfa (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Proof of concept; Therapeutic Use
- Acronyms explorer™4
- Sponsors Novo Nordisk
- 14 Dec 2021 Results (N=61) from phase 2 trials explorer4 (NCT03196284) and explorer5 (NCT03196297) describing surgeries and diagnostic procedures presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Results of an exploratory pooled analyses (of explorer4 (NCT03196284) and explorer5 (NCT03196297) phase 2 trials) assessing changes in HRQoL after long-term concizumab treatment presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 08 Dec 2020 Results from the extension part assessing safety and longer term efficacy presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology